This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer | MicrobiomeTrials
← Back to trials NCT07667400
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer Recruiting PHASE1, PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-10-29Est. Completion: 2036-10-01
Enrollment target: 120 participantsLocations National Institutes of Health Clinical Center, Bethesda, Maryland, United States Other microbiome trials you might be interested in Esophageal Squamous Cell Carcinoma Immunotherapy Biomarkers
To evaluate the efficacy and safety of adebrelimab with or without induction chemotherapy followed by concurrent chemora…
Fuzhou, China Est. completion Dec 2027
Carcinoma, Neuroendocrine Tumor, Neuroendocrine Tumors, Neuroendocrine Neuroendocrine; Carcinoma Small Cell; Receptors
Background:
High-grade neuroendocrine carcinomas (HGNEC) are cancers that develop in different parts of the body, inclu…
Bethesda, United States Est. completion Jul 30, 2027